Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | ADK | P55263 | 2/20 | 0.37 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
| ▸ | POLRMT | O00411 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25584077 | 0.95 | CYP3A4 (0.36) | CYP3A4CYP2C9ADKDOT1LPOLRMT | |
| SCHEMBL26282459 | 0.93 | CYP3A4 (0.40) | CYP3A4CYP2C9DOT1LPOLRMT | |
| SCHEMBL21283660 | 0.92 | CYP3A4 (0.42) | CYP3A4CYP2C9POLRMT | |
| SCHEMBL25584428 | 0.91 | CYP3A4 (0.39) | CYP3A4CYP2C9ADKDOT1L | |
| SCHEMBL25584095 | 0.91 | CYP3A4 (0.41) | CYP3A4CYP2C9ADKKRAS | |
| SCHEMBL26288028 | 0.90 | CYP3A4 (0.42) | CYP3A4CYP2C9POLRMT | |
| SCHEMBL26288030 | 0.90 | CYP3A4 (0.42) | CYP3A4CYP2C9POLRMT | |
| SCHEMBL25584090 | 0.90 | ADK (0.35) | ADKDOT1LPOLRMTKRAS | |
| SCHEMBL24120253 | 0.89 | CYP3A4 (0.40) | CYP3A4CYP2C9POLRMTKRAS | |
| SCHEMBL24088384 | 0.89 | CYP3A4 (0.40) | CYP3A4CYP2C9POLRMTKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183282-A1 | REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-06-15 | — | — | US | disclosed |
| US-20230183282-A1 | REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183282-A1 | REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS | ALB, ACE, ACE2 | CYP3A4 187/4885CYP2C9 288/4885ADK 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.